The life sciences investment outlook this year appears a bit conservative – if not muted – according to Cushman & Wakefield global research manager Sandy Romero.
Still considered a "relatively attractive" industry for investment, Romero said the capital would also be "chasing stability and looking more closely for strong financials" such as clinical trial successes as opportunistic plays continue to exist across all industry types.
She said that US dry powder in venture capital increased to $290.1 billion at the end of the third quarter of 2022. Looking at the past 10 years, it can be estimated that about 16% (or $46.4 billion) of the dry powder would be allocated toward life sciences. In 2021, life sciences investment totaled a record $50 billion.
Continue Reading for Free
Register and gain access to:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
*May exclude premium content
Already have an account?
Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
